Unlocking AI Spatial Biomarkers & Diagnostics for ADC Patient Selection
- Discussing how the MoA of ADCs and bispecifics warrant an AI-powered spatial biomarker approach for accurate patient selection
- Outlining how novel, AI-powered spatial biomarkers are being deployed for clinical trial enrollment
- Exploring how the exponential rise in ADC and bispecific trials and approvals will result in a new generation of diagnostics to aid physicians in treatment selection and what it means for drug developers